Get startedLog in
    Picture of Eli Lilly and logo

    LLY — Eli Lilly and News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Novo Says Ozempic Cuts Risk Of Major Cardiovascular Events

    Picture of Eli Lilly and logoEli Lilly and
    29/09/2026 15:13
    BRIEF-Novo Says Ozempic Cuts Risk Of Major Cardiovascular Events
    Sept 29 (Reuters) - Novo Nordisk A/S NOVOb.CO:
    • NOVO'S OZEMPIC (SEMAGLUTIDE) 2 MG ASSOCIATED WITH LOWER RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (DEATH, HEART ATTACK, AND STROKE) IN ADULTS WITH TYPE 2 DIABETES COMPARED TO SWITCHING TO MOUNJARO (TIRZEPATIDE), IN REAL-WORLD ANALYSIS AT EASD
    • SEMAGLUTIDE 2 MG DOSE ESCALATION LINKED TO 6% LOWER RISK OF MAJOR CARDIOVASCULAR EVENTS
    • OZEMPIC 2 MG ASSOCIATED WITH LOWER RISK OF MAJOR CARDIOVASCULAR EVENTS VERSUS MOUNJARO
    Source text: ID:nPnSjH8ka
    Further company coverage: [NOVOb.CO]

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Eli Lilly and

    See all news